Uveal Melanoma Research
  • The study: Moffitt researchers analyzed 60 advanced melanoma patients from four clinical trials to understand why TIL immunotherapy helps some patients but not others.
  • Cell quality matters: Infusions with more CD8+ T cells and “stem-like memory” T cells were linked to stronger responses.
  • A surprising marker: LAG-3, typically seen as a signal of T-cell “exhaustion,” was instead found on tumor-recognizing cells — a potential tool for improving future TIL products.
  • The tumor environment counts too: Tumors with tertiary lymphoid structures (mini immune hubs) were tied to longer survival and slower progression.
  • Timing may matter: Prior checkpoint inhibitor treatment was linked to fewer favorable T cells later available for TIL therapy, raising open questions about treatment sequencing.

For families navigating an ocular melanoma diagnosis, treatment options can feel like a moving target. A new study from Moffitt Cancer Center, led by Dr. Lilit Karapetyan and published in the journal Med, offers a clearer picture of one of those options: tumor-infiltrating lymphocyte, or TIL, therapy.

TIL therapy takes immune cells directly from a patient’s own tumor, grows them into the billions in a lab, and infuses them back into the body to fight the cancer. It has produced dramatic, lasting responses in some patients with advanced melanoma — but not everyone benefits, and doctors haven’t had a reliable way to predict who will.

By studying 60 patients across four early-stage clinical trials, the Moffitt team identified four factors that seemed to separate patients who responded from those who didn’t:

  • Infusions rich in CD8+ T cells, the immune system’s natural cancer killers, and “stem-like memory” T cells, which can keep replenishing the immune attack, tracked with better outcomes.
  • A protein called LAG-3, usually viewed as slowing T cells down, was instead found on the cells most likely to recognize a patient’s own tumor — a possible new marker for building stronger TIL products.
  • Tumors containing tertiary lymphoid structures, small immune hubs that resemble miniature lymph nodes, were linked to longer survival and slower disease progression.
  • Patients who had already received checkpoint inhibitor immunotherapy tended to have fewer of the helpful memory T cells available later for TIL manufacturing, raising questions about treatment sequencing.

Worth noting for our community: this study enrolled patients with advanced melanoma broadly, not ocular or uveal melanoma specifically. Still, TIL therapy is already being studied across melanoma types, and Dr. Karapetyan noted that the underlying biology likely matters regardless of where the melanoma started.

The takeaway isn’t a new treatment yet. It’s a clearer map of what researchers are chasing, and one more reason to ask your care team whether TIL therapy, or a related clinical trial, could be relevant to your specific case.

Studies like this one are exactly why staying connected to a specialized care team, and to research happening at centers like Moffitt, matters. Understanding is progress, even before it reaches the clinic.

Source: Moffitt Cancer Center, “New Moffitt Study Offers Clues to Why TIL Immunotherapy Works for Some Melanoma Patients but Not Others,” August 12, 2026.